Back to results
US 7,612,112 B2Granted
Methods of treatment using a gastric retained gabapentin dosage
AssigneeDepomed, Inc.
InventorsBret Berner, Sui Yuen Eddie Hou, Gloria M. Gusler
Life of this patent
Estimating the term…
Abstract
A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Claims18
An extended release oral drug dosage form for releasing gabapentin, comprising:
- a core comprising at least 800 mg of gabapentin, and
- a semipermeable membrane surrounding the core, the semipermeable membrane comprising a plasticizer and being permeable to a fluid in an environment of use and substantially impermeable to unsolubilized gabapentin,
- wherein the dosage form as formulated is of sufficient size for retention in the stomach in a fed mode for a period of at least about 5 hours, and wherein at least about 80 wt % of the gabapentin is released from the dosage form in about 5-12 hours via controlled release through the semipermeable membrane.
An extended release oral drug dosage form for releasing gabapentin into the stomach, duodenum and small intestine of a mammal, comprising:
- a core comprising at least 800 mg of gabapentin, and
- a semipermeable membrane surrounding the core, the semipermeable membrane comprising a plasticizer and being permeable to a fluid in an environment of use and substantially impermeable to unsolubilized gabapentin,
- wherein the dosage form as formulated is of sufficient size for retention in the stomach in a fed mode for a period of at least about 5 hours, and wherein at least about 80 wt % of the gabapentin is released from the dosage form in about 5-12 hours via controlled release through the semipermeable membrane.
Dependencies are inferred from the claim text.